PDF Cover

Glasdegib Market

The market for Glasdegib was estimated at $352 million in 2024; it is anticipated to increase to $631 million by 2030, with projections indicating growth to around $1.03 billion by 2035.

Report ID:DS1802245
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Glasdegib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Glasdegib Market Outlook

Revenue, 2024

$352M

Forecast, 2034

$930M

CAGR, 2025 - 2034

10.2%

The Glasdegib industry revenue is expected to be around $388.2 million in 2025 and expected to showcase growth with 10.2% CAGR between 2025 and 2034. The considerable projected expansion in the market for Glasdegib could be linked to its growing importance in the field of therapeutics. Key factors propelling this growth include advancements in research and development rising incidence of hematological malignancies and a growing worldwide embrace of targeted treatments. The sustained relevance of the market is further bolstered by progress in drug formulation technologies with Glasdegib effectiveness positioning it as a crucial tool, in combating certains of cancer.

Glasdegib, also known as Daurismo, is an inhibitor in the form of a small molecule that specifically focuses on disrupting the Hedgehog signaling pathway known to be involved in differents of cancer growths. It is mainly utilized to treat myeloid leukemia in adults due to its ease of oral intake and positive pharmacokinetic properties that make it a popular choice in cancer treatment circles. Furthermore a rising global interest in targeted therapies has led to an increased demand for Glasdegib, in times enrichening its market opportunities.

Glasdegib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Glasdegib Market Outlook

Market Key Insights

  • The Glasdegib market is projected to grow from $352.3 million in 2024 to $931 million in 2034. This represents a CAGR of 10.2%, reflecting rising demand across Acute Myeloid Leukemia Treatment, Management of Myelofibrosis, and Patients Unfit for Intensive Chemotherapy.

  • Pfizer Inc. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Glasdegib market and are expected to observe the growth CAGR of 7.4% to 10.7% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Korea are expected to observe highest growth with CAGR ranging between 9.8% to 12.8%.

  • Slow adoption of Personalized Medicine Revolution transition within key players in Glasdegib market is creating a revenue window for adjacent and alternate markets like Visudyne and Votrient to improve its use-case penetration in Oncology and Hematology applications and expected to capture $37 million revenue from existing Glasdegib market.

  • The Glasdegib market is set to add $578 million between 2024 and 2034, with manufacturer targeting Oncology Clinics & Cancer Research Institutes Application projected to gain a larger market share.

  • With Rising cancer prevalence, and technological Advancements, Glasdegib market to expand 164% between 2024 and 2034.

glasdegib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Glasdegib - Country Share Analysis

Opportunities in the Glasdegib

The growth of Glasdegib in developing markets like Asia presents another opportunity for expansion as these countries experience a rise in cancer cases and an increased need for treatments, like Glasdegib.

Growth Opportunities in North America and Europe

The Glasdegib market is mostly led by the American region because of major pharmaceutical companies and strong research efforts there that support it well ahead of the global competition. The demand for Glasdegib in this region is mainly fueled by the occurrence of diseases like acute myeloid leukemia that it targets. Factors such as healthcare spending levels and advanced healthcare facilities in addition to growing awareness about cutting edge oncology treatments are also key drivers behind market expansion, in this region. The rivalry, in this region is intense as major companies continually invest in cutting edge research methods to develop formulations of Glasdegib.
Glasdegib has a presence in the European market due to advancements in targeted therapies and increased investment in healthcare infrastructure driving its popularity up considerably. The rising number of individuals prone to variouss of cancers like hematological malignancies is also contributing to the growing demand for Glasdegib. Health organizations in the region are actively working to improve access to drug therapies which gives Glasdegib a competitive edge in the market. Competition is fierce, among industry leaders who are focusing on forming alliances and partnerships to enhance their market reach and presence.

Market Dynamics and Supply Chain

01

Driver: Increasing Incidence of Acute Myeloid Leukemia and Expanded Targeted Therapy Adoption

One of the primary drivers for Glasdegib’s market growth is also the rising incidence of acute myeloid leukemia, particularly among aging populations globally. As life expectancy increases, the number of elderly patients diagnosed with AML who are also ineligible for intensive chemotherapy grows, expanding the addressable patient pool for targeted, less intensive therapies like Glasdegib plus low‑dose cytarabine. Concurrently, there is also a strong industry trend toward targeted therapy adoption in oncology, driven by also advances in molecular biology and precision medicine that enable drugs to act on specific signaling pathways such as Hedgehog. Glasdegib’s mechanism of inhibiting the Hedgehog pathway resonates with precision oncology’s rise, highlighting the preference for treatments with defined biological targets and improved safety profiles in vulnerable populations. These trends collectively expand clinical utilization and incentivize continued investment in novel targeted agents that fill critical therapeutic gaps in hematologic malignancies.
A key driver in the Glasdegib market is also the advancement of oral small molecule inhibitor technology, which improves patient convenience and broadens treatment accessibility. Oral administration allows patients, especially elderly or frail individuals, to avoid frequent hospital visits required for intravenous therapies, enhancing quality of life and adherence. Pharmaceutical advancements in formulation and delivery have also optimized oral bioavailability and metabolic stability, making targeted agents like Glasdegib viable outpatient options. This trend aligns with healthcare’s shift toward patient‑centric care models and supports wider adoption of oral targeted therapies beyond traditional chemotherapy, influencing prescribing behavior and market demand.
02

Restraint: Limited Patient Eligibility and Narrow Approved Indications Restrict Glasdegib Market Reach

Glasdegib’s current regulatory approval is narrowly focused on newly diagnosed acute myeloid leukemia patients who are unfit for intensive chemotherapy, significantly limiting the addressable patient population. This restricted indication means that many AML patients with different risk profiles or fitness levels are not candidates for Glasdegib therapy, constraining overall demand. Healthcare providers may prefer broader‑spectrum or combination regimens with wider applicability, reducing prescription uptake. As a result, Glasdegib’s sales growth and market penetration remain modest compared with other AML therapies with broader labels, affecting revenue potential and slowing market expansion.
03

Opportunity: Targeted Therapies in Oncology and Forging Strategic Partnerships

Glasdegib is considered an addition to the expanding field of targeted therapy in cancer treatment due to its role as a Hedgehog pathway inhibitor. Its effectiveness in addressing blood related cancers like Acute Myeloid Leukemia and Myelodysplastic Syndromes for individuals who are unable-to undergo aggressive chemotherapy regimens positions it as an important choice in personalized medical care. The promising combination of an overlooked group of patients and a revolutionary treatment strategy ensures a market, for Glasdegib.
Glasdegib aims to strengthen its presence in the specialized treatments sector. May look to broaden its market reach by team up with other biopharmaceutical firms strategically for joint endeavors that could enhance the scope of Glasdegib uses through combined therapies and ultimately increase its effectiveness, in treating patients.
04

Challenge: High Treatment Costs and Reimbursement Challenges Limit Healthcare Adoption and Access

Another key restraint is the high cost of Glasdegib regimens combined with inconsistent reimbursement policies across regions. Targeted oncology agents like Glasdegib often come with premium pricing, which can strain hospital budgets and patient access, especially in developing markets or healthcare systems with tight cost controls. Payers may demand stringent cost‑effectiveness evidence before granting coverage, delaying adoption in clinical practice. This economic barrier influences prescribing behavior, with clinicians sometimes opting for more established or better‑reimbursed treatments, which reduces overall uptake and impacts revenue growth for Glasdegib.

Supply Chain Landscape

1

Raw Material Procurement

PfizerJubilant Pharma
2

Production

Pfizer IncApotex Inc
3

Quality Check & Packaging

Sun PharmaceuticalsZydus Pharmaceuticals
4

Distribution & retail

CVS PharmacyWalgreens Pharmacy
Glasdegib - Supply Chain

Use Cases of Glasdegib in Acute Myeloid Leukemia Treatment & Patients Unfit for Intensive Chemotherapy

Acute Myeloid Leukemia Treatment : Glasdegib, marketed as Daurismo, is an oral Hedgehog pathway inhibitor used in combination with low‑dose cytarabine to treat newly diagnosed acute myeloid leukemia in adults who are elderly (≥ 75 years). By blocking the Hedgehog signaling pathway, Glasdegib helps reduce leukemic cell growth and improve overall survival compared to cytarabine alone. Its targeted mechanism and oral administration provide a valuable alternative for patients with limited treatment options, with Pfizer leading the market through Daurismo’s regulatory approvals and oncology portfolio presence.
Management of Myelofibrosis : While not a standard approved indication, research use of Glasdegib in myelofibrosis reflects interest in targeting aberrant signaling pathways in complex hematologic conditions. Early open‑label phase 1b/2 trials have explored Glasdegib as monotherapy or in combination with other agents in patients with primary or secondary myelofibrosis previously treated with other therapies like ruxolitinib. These studies aim to assess safety, spleen volume reduction, and symptom improvements, potentially expanding its utility in rare myeloproliferative disorders beyond AML.
Patients Unfit for Intensive Chemotherapy : Glasdegib’s most significant application is in patients unfit for intensive induction chemotherapy, such as those with comorbidities or advanced age. In this population, standard high‑dose regimens carry substantial toxicity risk. Combined with low‑dose cytarabine, Glasdegib provides a less intensive, targeted therapy option, improving treatment tolerance while still offering clinical benefit. This niche fills a critical gap in oncology, allowing patients who would otherwise be ineligible for curative regimens to receive effective, personalized leukemia care.

Recent Developments

Recent developments for Daurismo show continued emphasis on expanding its role in targeted leukemia treatment and improving supportive oncology care for patients unfit for intensive chemotherapy. A key market trend is the growth of precision medicine and oral small molecule inhibitors, which enable tailored therapies with improved tolerability and convenience compared to traditional chemotherapy. Increasing research into combination regimens and molecularly guided treatment strategies further supports Glasdegib’s clinical relevance in hematologic malignancies and strengthens its position in the evolving cancer drug landscape.

December 2023 : Pfizer completed the acquisition of Seagen, an oncology‑focused biopharmaceutical company, in late 2023, adding Seagen’s antibody‑drug conjugate (ADC) therapies to its portfolio. While not specific to glasdegib, this major move expanded Pfizer’s cancer treatment capabilities and commercial reach, strengthening its position in hematologic and solid tumor therapies and enhancing cross‑selling potential for oncology products like Daurismo.
May 2025 : Pfizer entered a global licensing agreement with 3SBio to develop and commercialize SSGJ‑707, a PD‑1/VEGF dual‑targeting antibody. Although this is outside direct glasdegib action, the deal demonstrates Pfizer’s strategic expansion in oncology, which can bolster its competitive portfolio and support broader cancer care solutions.

Impact of Industry Transitions on the Glasdegib Market

As a core segment of the Pharmaceutical industry, the Glasdegib market develops in line with broader industry shifts. Over recent years, transitions such as Personalized Medicine Revolution and Technological Advancements in Drug Discovery have redefined priorities across the Pharmaceutical sector, influencing how the Glasdegib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Personalized Medicine Revolution

The field of cancer treatment is undergoing a transformation with the rise of precision medicine and genomics technologies in recent years. One noticeable shift in oncology is towards personalized therapy methods where Glasdegib stands out as an effective medication for certain cancers. This drug targets molecular signaling pathways. Shows promise in treating specific cancer subtypes by considering individual patients’ genetic makeup. Its importance is increasingly recognized in settings for handling conditions, like myelodysplastic syndromes and acute myeloid leukemia. The shift towards medicine is anticipated to have a beneficial influence on related sectors such as genomics research and pharmaceutical manufacturing, within the biotechnology field.
02

Technological Advancements in Drug Discovery

The Glasdegib market has benefited significantly from technological advancements in drug discovery, which have transformed oncology R&D and accelerated the development of targeted therapies. Tools like high-throughput screening, artificial intelligence, and machine learning enable rapid identification of promising compounds and optimization of pharmacologic properties. For Glasdegib, these technologies facilitated the discovery of its Hedgehog pathway inhibitory activity, allowing Pfizer and collaborating partners to streamline preclinical testing and clinical trial design. Beyond AML, AI-driven modeling and predictive analytics are now being applied in hematology and rare disease drug development, enhancing efficiency, reducing costs, and improving success rates, ultimately driving innovation and faster availability of novel targeted therapies across pharmaceutical and biotech industries.